Patents by Inventor Jesper Worm

Jesper Worm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MICRORNA-134 BIOMARKER
    Publication number: 20260159889
    Abstract: The invention relates to the field of secondary markers for microRNA activity, and in particular the invention relates to the identification of Serpine1 as a mRNA which is repressed by microRNA-134 in neuronal cells, and the use of Serpine1 mRNA or protein as a biomarker for microRNA-134 modulation, such as a biomarker for antisense oligonucleotide inhibitors of microRNA-134.
    Type: Application
    Filed: August 1, 2025
    Publication date: June 11, 2026
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Jesper WORM, Lukasz KIELPINSKI
  • ANTISENSE OLIGONUCLEOTIDES FOR TARGETING PROGRANULIN
    Publication number: 20260132403
    Abstract: Antisense oligonucleotides for altering the splicing pattern of progranulin, and their use in the treatment of neurological disorders. The antisense oligonucleotides are modified to better increase up-regulation or expression restoration of the Exon1-Exon2 progranulin splice variant in cells.
    Type: Application
    Filed: December 16, 2024
    Publication date: May 14, 2026
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jesper WORM, Lars JOENSON, Mads MANSØ, Dorthe VANG
  • ANTISENSE OLIGONUCLEOTIDES FOR TARGETING PROGRANULIN
    Publication number: 20250361507
    Abstract: Antisense oligonucleotides for altering the splicing pattern of progranulin, and their use in the treatment of neurological disorders. The antisense oligonucleotides are modified to better increase up-regulation or expression restoration of the Exon1-Exon2 progranulin splice variant in cells.
    Type: Application
    Filed: December 16, 2024
    Publication date: November 27, 2025
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jesper WORM, Lars JOENSON, Mads MANSØ, Dorthe VANG
  • Antisense Oligonucleotide for Targeting Progranulin
    Publication number: 20250346894
    Abstract: The present invention relates to oligonucleotides which alter the splicing pattern of progranulin in cells, and their use in the treatment of neurological disorders.
    Type: Application
    Filed: August 20, 2024
    Publication date: November 13, 2025
    Inventors: Ravi Jagasia, Lars Jonson, Soren Rasmussen, Jacob Ravn, Disa Tehler, Dorthe Vang, Jesper Worm
  • MicroRNA-134 biomarker
    Patent number: 12421552
    Abstract: The invention relates to the field of secondary markers for microRNA activity, and in particular the invention relates to the identification of Serpine1 as a mRNA which is repressed by microRNA-134 in neuronal cells, and the use of Serpine1 mRNA or protein as a biomarker for microRNA-134 modulation, such as a biomarker for antisense oligonucleotide inhibitors of microRNA-134.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: September 23, 2025
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Jesper Worm, Lukasz Kielpinski
  • DOUBLE-STRANDED RNA MOLECULE FOR ADMINISTRATION TO THE EYE
    Publication number: 20250250571
    Abstract: The present invention relates to double-stranded RNA molecules conjugated to at least one conjugate moiety for topical administration to the eye, and pharmaceutical compositions thereof. The double-stranded RNA molecules are complementary, such as fully complementary, to targets expressed in the eye, and are capable of inhibiting expression of targets expressed in the eye. The double-stranded RNA molecules can be used in the treatment of conditions and diseases of the eye.
    Type: Application
    Filed: February 18, 2025
    Publication date: August 7, 2025
    Inventors: Konrad BLEICHER, Erik FUNDER, Helle JACOBSEN, Dennis Jul HANSEN, Michael KELLER, Inna Appeldorff LARSEN, Tiago Francisco SANTOS FERREIRA, Lotte WINTHER, Jesper WORM, Lena WYSS
  • ANTISENSE OLIGONUCLEOTIDES FOR TARGETING PROGRANULIN
    Publication number: 20250188462
    Abstract: Antisense oligonucleotides for altering the splicing pattern of progranulin, and their use in the treatment of neurological disorders. The antisense oligonucleotides are modified to better increase up-regulation or expression restoration of the Exon1-Exon2 progranulin splice variant in cells.
    Type: Application
    Filed: December 16, 2024
    Publication date: June 12, 2025
    Inventors: Jesper WORM, Lars JOENSON, Mads MANSØ, Dorthe VANG
  • OLIGONUCLEOTIDE AGONISTS TARGETING PROGRANULIN
    Publication number: 20250136984
    Abstract: The present invention relates to oligonucleotides which up-regulate or restore the expression of progranulin in cells, and their use in the treatment of neurological disorders, and disorders associated with progranulin haploinsufficiency.
    Type: Application
    Filed: October 2, 2024
    Publication date: May 1, 2025
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ravi JAGASIA, Lars JOENSON, Søren RASMUSSEN, Disa TEHLER, Dorthe Vang LARSEN, Jesper WORM
  • Antisense Oligonucleotide for Targeting Progranulin
    Publication number: 20250051772
    Abstract: The present invention relates to oligonucleotides which alter the splicing pattern of progranulin in cells, and their use in the treatment of neurological disorders.
    Type: Application
    Filed: August 20, 2024
    Publication date: February 13, 2025
    Inventors: Ravi Jagasia, Lars Jonson, Soren Rasmussen, Jacob Ravn, Disa Tehler, Dorthe Vang, Jesper Worm
  • Double Stranded Oligonucleotide For Modulating JAK1 Expression
    Publication number: 20250034576
    Abstract: The present invention relates to double stranded oligonucleotides that are complementary to JAK1, leading to modulation of the expression of JAK1. Modulation of JAK1 expression is beneficial for a range of medical disorders including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. Also included are compositions comprising the double stranded oligonucleotide and methods of treatment using the double stranded oligonucleotide.
    Type: Application
    Filed: June 14, 2024
    Publication date: January 30, 2025
    Inventors: Philipp Friedrich BERNINGER, Konrad BLEICHER, Erik FUNDER, Helle JACOBSEN, Dennis Jul HANSEN, Michael KELLER, Inna Appeldorff LARSEN, Meiling LI, Disa Elisabet TEHLER, Lotte WINTHER, Jesper WORM, Lena WYSS, Tiago Francisco SANTOS FERREIRA
  • Oligonucleotide agonists targeting progranulin
    Patent number: 12203071
    Abstract: The present invention relates to oligonucleotides which up-regulate or restore the expression of progranulin in cells, and their use in the treatment of neurological disorders, and disorders associated with progranulin haploinsufficiency.
    Type: Grant
    Filed: May 13, 2021
    Date of Patent: January 21, 2025
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ravi Jagasia, Lars Joenson, Søren Rasmussen, Disa Tehler, Dorthe Vang Larsen, Jesper Worm
  • Antisense oligonucleotide for targeting progranulin
    Patent number: 12104153
    Abstract: The present invention relates to oligonucleotides which alter the splicing pattern of progranulin in cells, and their use in the treatment of neurological disorders.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: October 1, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ravi Jagasia, Lars Jonson, Soren Rasmussen, Jacob Ravn, Disa Tehler, Dorthe Vang, Jesper Worm
  • Oligonucleotide Agonists Targeting Progranulin
    Publication number: 20230287412
    Abstract: The present invention relates to oligonucleotides which up-regulate or restore the expression of progranulin in cells, and their use in the treatment of neurological disorders, and disorders associated with progranulin haploinsufficiency.
    Type: Application
    Filed: November 14, 2022
    Publication date: September 14, 2023
    Inventors: Ravi Jagasia, Lars Joenson, Soren Rasmussen, Disa Tehler, Dorthe Vang Larsen, Jesper Worm
  • OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE
    Publication number: 20230002762
    Abstract: The present invention relates to an oligonucleotide comprising at least one phosphorodithioate internucleoside linkage of formula (I) (I) as defined in the description and in the claim. The oligonucleotide of the invention can be used as a medicement.
    Type: Application
    Filed: April 14, 2022
    Publication date: January 5, 2023
    Applicant: ROCHE INNOVATION CENTER COPENHAGEN A/S
    Inventors: Konrad Bleicher, Henrik Frydenlund HANSEN, Troels KOCH, Jesper WORM, Adrian SCHAEUBLIN, Erik FUNDER, Joerg DUSCHMALÉ, Lars JOENSON, Meiling LI, Martina Brigitte DUSCHMALÉ, Yong WU, Xi SHU
  • Oligonucleotide Progranulin Agonists
    Publication number: 20220403388
    Abstract: The present invention relates to oligonucleotides that upregulate or restore the expression of progranulin in cells by targeting the promoter region of the progranulin gene. The invention further relates to pharmaceutical compositions and methods for the treatment of diseases associated with progranulin, specifically progranulin haploinsufficiency and neurological disorders.
    Type: Application
    Filed: June 6, 2022
    Publication date: December 22, 2022
    Inventors: Lars Joenson, Soren V. Rasmussen, Jesper Worm, Dorthe Vang Larsen, Johannes Braun
  • Antisense Oligonucleotide for Targeting Progranulin
    Publication number: 20220204973
    Abstract: The present invention relates to oligonucleotides which alter the splicing pattern of progranulin in cells, and their use in the treatment of neurological disorders.
    Type: Application
    Filed: December 16, 2021
    Publication date: June 30, 2022
    Inventors: Ravi Jagasia, Lars Jonson, Soren Rasmussen, Jacob Ravn, Disa Tehler, Dorthe Vang, Jesper Worm
  • OLIGONUCLEOTIDE AGONISTS TARGETING PROGRANULIN
    Publication number: 20210388357
    Abstract: The present invention relates to oligonucleotides which up-regulate or restore the expression of progranulin in cells, and their use in the treatment of neurological disorders, and disorders associated with progranulin haploinsufficiency.
    Type: Application
    Filed: May 13, 2021
    Publication date: December 16, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ravi JAGASIA, Lars JOENSON, Søren RASMUSSEN, Disa TEHLER, Dorthe Vang LARSEN, Jesper WORM
  • MICRORNA-134 BIOMARKER
    Publication number: 20210270845
    Abstract: The invention relates to the field of secondary markers for microRNA activity, and in particular the invention relates to the identification of Serpine1 as a mRNA which is repressed by microRNA-134 in neuronal cells, and the use of Serpine1 mRNA or protein as a biomarker for microRNA-134 modulation, such as a biomarker for antisense oligonucleotide inhibitors of microRNA-134.
    Type: Application
    Filed: February 23, 2021
    Publication date: September 2, 2021
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Jesper Worm, Lukasz Kielpinski
  • OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE
    Publication number: 20200339982
    Abstract: The present invention relates to an oligonucleotide comprising at least one phosphorodithioate internucleoside linkage of formula (I) (I) as defined in the description and in the claim. The oligonucleotide of the invention can be used as a medicament.
    Type: Application
    Filed: December 21, 2018
    Publication date: October 29, 2020
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Konrad BLEICHER, Henrik Frydenlund HANSEN, Troels KOCH, Jesper WORM, Adrian SCHAEUBLIN, Erik FUNDER, Joerg DUSCHMALÉ, Lars JOENSON, Meiling LI, Martina Brigitte DUSCHMALÉ, Yong WU, Xi SHU
  • METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS
    Publication number: 20140031409
    Abstract: The invention provides the combination use of antisense oligomers targeting androgen receptor mRNA and androgen receptor binding inhibitors that reduce androgen receptor activity for the treatment of androgen receptor related medical disorders, such as cancers, particularly prostate cancers and breast cancers.
    Type: Application
    Filed: April 30, 2013
    Publication date: January 30, 2014
    Applicants: Santaris Pharma A/S, Enzon Pharmaceuticals
    Inventors: Jesper Worm, Yixian Zhang